Shots: Approval is based on three clinical trials (N=80) assessing safety, tolerability, PK, haemostatic efficacy of rVWF in adults: P-III for rFVIII with severe VWD; P-III for rFVIII and rVWF in the treatment of bleeding episodes with severe VWD; P-III with severe VWD undergoing major/ minor/oral elective surgical procedures (w/o rFVIII) VEYVONDI [vonicog alfa, recombinant […]Read More
Tags : VEYVONDI
Latest Posts
Categories
Related Topics
AbbVie
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborate
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
EU
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US